ArticleAntiviral research2013
Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid.
Article in Antiviral research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Segmented, Negative-Sense RNA Viruses of Humans: Genetic Systems and Experimental Uses of Reporter Strains.Annual review of virology · 2023Review
- Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.Antimicrobial agents and chemotherapy · 2023Article
- Article
- Article
- Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity.Clinical epigenetics · 2021Article
- Progress in Anti-Mammarenavirus Drug Development.Viruses · 2021Review
- Valproic Acid and Its Amidic Derivatives as New Antivirals against Alphaherpesviruses.Viruses · 2020Review
- Clinical Infections by Herpesviruses in Patients Treated with Valproic Acid: A Nested Case-Control Study in the Spanish Primary Care Database, BIFAP.Journal of clinical medicine · 2019Article
- The ReFRAME library as a comprehensive drug repurposing library to identify mammarenavirus inhibitors.Antiviral research · 2019Article
- Inhibition of Porcine Viruses by Different Cell-Targeted Antiviral Drugs.Frontiers in microbiology · 2019Article
- Arenavirus Quasispecies and Their Biological Implications.Current topics in microbiology and immunology · 2016Review
- Identification and Mechanism of Action of a Novel Small-Molecule Inhibitor of Arenavirus Multiplication.Journal of virology · 2015Article
- New pharmacological strategies to fight enveloped viruses.Trends in pharmacological sciences · 2014Review
- Sodium hydrogen exchangers contribute to arenavirus cell entry.Journal of virology · 2014Article
- Insights into bioinformatic approaches for repurposing compounds as anti-viral drugs.Antiviral chemistry & chemotherapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Valproic acid (VPA), a short chain fatty acid commonly used for treatment of neurological disorders, has been shown to inhibit production of infectious progeny of different enveloped viruses including the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). In this study we have investigated the mechanisms by which VPA inhibits LCMV multiplication in cultured cells. VPA reduced production of infectious LCMV progeny and virus propagation without exerting a major blockage on either viral RNA or protein synthesis, but rather affecting the cell release and specific infectivity of LCMV progeny from infected cells. Our results would support the repurposing of VPA as a candidate antiviral drug to combat arenavirus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.